In sarcoidosis patients there was expansion of the intermediate CD14++/CD16+ monocyte population (13.6% ± 1.01 (mean ± SEM) compared with 9.3% ± 0.82, p < 0.05) and reduction in classical CD14++/CD16− monocytes (78.1% ± 1.13 compared with 83.6% ± 2.01, p < 0.01) (Fig. 4). This evidence concerns the gene CD14 and sarcoidosis.